Spectral Medical Inc.
TSX:EDT.TOMedical - Diagnostics & Research
-$0.02 today
- Market cap
- $306.00M
- Beta
- 0.23
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.13
Volume 0.02M
Average 0.06M
EDT.TO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Spectral Medical Inc.TSX: EDT.TO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of CA$63K rose 5.0% year over year, ahead of the +1.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Depreciation & amortization amounted to 10.2% of revenue in FY2025, down 0.7 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +5.0% holds above the trailing-twelve-month pace of +1.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
CAD · from the cash flow
- Latest · FY2025
- 250K CAD
- Year-over-year change
- -0.4%
- 4-year CAGR
- -4.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 250K | -0.4% |
| FY2024 | 2024-12-31 | 251K | +15.1% |
| FY2023 | 2023-12-31 | 218K | -19.9% |
| FY2022 | 2022-12-31 | 272K | -7.5% |
| FY2021 | 2021-12-31 | 294K | — |
Depreciation & Amortization vs competitors
How EDT.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.6% is the 4th highest of 8, against a peer median of -1.0%.
- Depreciation & amortization amounts to 9.2% of revenue for EDT.TO, versus a peer median of 8.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$40.12M CAD | -6.9% | -23.0% | 12.9% | |
| LTM Mar 2026 | CA$14.91M CAD | +33.9% | +34.9% | 22.4% | |
| LTM Mar 2026 | CA$14.19M CAD | -37.1% | -31.2% | 4.5% | |
| LTM Mar 2026 | $7.22M USD | +30.0% | +94.1% | 14.2% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $497.04K USD | -32.9% | -29.2% | 2.6% |
| LTM Mar 2026 | $263.19K USD | +45.4% | +6.5% | — | |
| LTM Mar 2026 | CA$253K CAD | +1.6% | -2.8% | 9.2% | |
| LTM Mar 2026 | $101.93K USD | -1.0% | — | 0.2% | |
| Peer median (excluding EDT.TO) | — | -1.0% | -8.3% | 8.7% | |
Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.79M) | (11.25M) | (15.66M) | (15.4M) | (47.69M) |
| Depreciation & Amortization | 294K | 272K | 218K | 251K | 250K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.26M | 1.2M | 1.49M | 1.68M | 2.12M |
| Change in Working Capital | (1.76M) | 579K | (406K) | 1.01M | (189K) |
| Accounts Receivables | 55K | (877K) | 870K | (265K) | 246K |
| Inventory | (51K) | (47K) | (26K) | 137K | (148K) |
| Accounts Payables | (1.11M) | 1.65M | (267K) | (51K) | (265K) |
| Other Working Capital | (656K) | (142K) | (983K) | 1.19M | (22K) |
| Other Non-Cash Items | 288K | (698K) | 3.64M | 3.64M | 33.88M |
| Operating Cash Flow | (8.7M) | (9.9M) | (10.72M) | (8.82M) | (9.52M) |
| Capital Expenditures | (483K) | (33K) | (185K) | (27K) | (195K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 158K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (325K) | (33K) | (185K) | (27K) | (195K) |
| Debt Repayment | (113K) | 3.71M | 3.93M | 9.74M | 9.67M |
| Common Stock Issued | 10M | 4.03M | 0 | 1.15M | 3.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.28M | 1.72M | 1.51M | (2.02M) | (155K) |
| Financing Cash Flow | 12.17M | 9.46M | 5.44M | 8.88M | 12.91M |
| Effect of Forex Changes | (56K) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.08M | (476K) | (5.46M) | 36K | 1.08M |
| Free Cash Flow | (9.18M) | (9.93M) | (10.91M) | (8.85M) | (9.72M) |
Spectral Medical Inc.
TSX:EDT.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.